How Investors Are Reacting To Daiichi Sankyo Company (TSE:4568) New Real-World Bempedoic Acid Cardiovascular Data

• Daiichi Sankyo recently reported new real-world data from the multinational MILOS study at the European Society of Cardiology 2026 Congress in Munich, showing that bempedoic acid, alone or with ezetimibe, produced clinically relevant LDL-C reductions and estimated 10-year cardiovascular risk reductions in dyslipidaemia patients.
• The findings highlight that bempedoic acid-based regimens delivered consistent LDL-C lowering and risk estimates across sexes and glycaemic profiles, reinforcing its potential role in everyday cardiovascular care.
• We’ll now examine how this real-world cardiovascular evidence for bempedoic acid interacts with Daiichi Sankyo’s oncology-focused investment narrative and pipeline.

Rare earth metals are the new gold rush. Find out which 30 stocks are leading the charge.

Daiichi Sankyo Company Investment Narrative Recap

To own Daiichi Sankyo, you need to believe its oncology franchise (ENHERTU, Datroway) and ADC pipeline can offset revenue concentration and pricing pressure risks over time. The MILOS real-world cardiovascular data supports the breadth of the portfolio but does not materially change the near term focus on oncology trial readouts and regulatory decisions as the key catalysts, nor the reliance on a few flagship cancer drugs as the primary business risk.

The most relevant related development is Daiichi Sankyo’s creation of a new global Commercialization Unit, aimed at supporting about 20 new indications across five medicines by 2030. In that context, the MILOS results help show there is more to the story than oncology alone, but investor attention is still likely to center on how this new commercial structure supports upcoming ENHERTU and Datroway launches and any future bempedoic acid uptake.

Yet while the oncology story looks compelling, investors should be aware that concentrated reliance on a handful of drugs could…

Read the full narrative on Daiichi Sankyo Company (it’s free!)

Daiichi Sankyo Company’s narrative projects ¥2638.7 billion revenue and ¥330.7 billion earnings by 2029.

Uncover how Daiichi Sankyo Company’s forecasts yield a ¥4146 fair value, a 41% upside to its current price.

Exploring Other Perspectives

Some analysts are far more optimistic than consensus, assuming revenue could reach about ¥3,121.2 billion and earnings ¥470.8 billion by 2029, arguing that faster oncology growth and margin expansion might outweigh risks like heavy dependence on ENHERTU and Datroway. With the new cardiovascular data and evolving pipeline, you should expect that both bullish and baseline narratives may shift and consider how different these viewpoints really are.

Explore 3 other fair value estimates on Daiichi Sankyo Company – why the stock might be worth as much as 71% more than the current price!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

Ready To Venture Into Other Investment Styles?

Don’t miss your shot at the next 10-bagger. Our latest stock picks just dropped:

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com